National Cancer Institute (NCI) - Recruiting N/A to 21 years. - A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG).
National Cancer Institute (NCI) - Recruiting 37 Months to 21 years. - A Phase 1 Study of MK-1775 Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas.
Roswell Park Cancer Institute - Recruiting 18 years or older. - A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors.
DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis
Roswell Park Cancer Institute - Recruiting 18 years or older. - Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas.
Beth Israel Medical Center - Recruiting 18 years to 70 years. - STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial.
Tocagen Inc. - Recruiting 18 years to 80 years. - A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Nave Patients With Recurrent Glioblastoma Multiforme.
anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study
Pediatric Brain Tumor Consortium - Recruiting 16 years to 21 years. - A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG).
Northwestern University - Recruiting 18 years or older. - A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas.
Weill Medical College of Cornell University - Recruiting 18 years or older. - Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.
Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Weill Medical College of Cornell University - Recruiting 18 years or older. - Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma.